Phase 3 Readout
NAMS: Phase 3 Topline: A Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/
February 1, 2028 · atherosclerotic. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- February 1, 2028
- Company
- NEWAMSTERDAM PHARMA CO N.V. (NAMS)
- Drug
- atherosclerotic
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/
- Drug
- atherosclerotic
- Indication
- Coronary Artery Disease; Plaque, Atherosclerotic; Lipidemia